ALD 401

Drug Profile

ALD 401

Alternative Names: ALD401; ALDHbr

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aldagen
  • Class Anti-ischaemics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 05 May 2014 Discontinued - Phase-II for Stroke in USA (Intracarotid)
  • 31 Mar 2014 ALD 401 is available for licensing as of 31 Mar 2014.
  • 06 Jan 2014 Cytomedix completes enrolment in the phase III RECOVER-Stroke trial for Stroke in USA (NCT01273337)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top